Astellas To Rename Succin To Avoid Confusion With Kowa Drug
This article was originally published in PharmAsia News
Executive SummaryAstellas Pharma is renaming its Succin (solefenacin) muscle relaxant to Suxamethonium to avoid a repeat of a fatal mistake by a hospital in Japan last year. It was decided the name of the drug was too similar to Kowa's Saxizon (hydrocortisone), and the cause of the mistake behind the stronger Succin given to the patient. Astellas had resisted renaming its drug, saying warnings and greater care would suffice, but critics said warnings were not enough and that similar mistakes could occur. (Click here for more
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.